"We need to embrace the challenges that creating truly diverse, patient-focused clinical trials brings," says a drug development expert with more than 40 years of insight on the matter.
To truly be patient-centered, clinical trials must include all patients; but how can organizations in the industry increase diversity?
Decentralized clinical trials are evolving beyond their utility in pandemic conditions into what looks to be an ongoing and potentially game-changing presence in the clinical research enterprise.
We need a better understanding of the abilities and willingness of site staff and principal investigators to perform the new duties and responsibilities entailed in decentralized clinical trials.
While technology considerations are important to onboarding new staff, they are also crucial throughout the duration of employment to offboarding, experts warn.